COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)

Vicent, Marta González; Martínez, A. Pérez; Castillo, María; Molina, Blanca; Sisini, Luisa; Morón‐Cazalilla, Georgina; Díaz, Miguel Ángel

doi:10.1002/pbc.28514

Cited by 62 publications

(94 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, data on outcomes of HSCT recipients with COVID-19 are limited to small case series and single-centre experiences. 8 , 9 , 10 , 11 , 12 Better characterisation of HSCT patients infected with SARS-CoV-2 is needed. Here we describe the clinical characteristics, treatment patterns, and factors associated with outcomes of HSCT recipients who developed COVID-19 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Sharma

Bhatt

Martin³

et al. 2021

The Lancet Haematology

320

408

View full text Add to dashboard Cite

Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19. MethodsIn response to the pandemic, the Center for International Blood and Marrow Transplant Research (CIBMTR) implemented a special form for COVID-19-related data capture on March 27, 2020. All patients-irrespective of age, diagnosis, donor type, graft source, or conditioning regimens-were included in the analysis with data cutoff of Aug 12, 2020. The main outcome was overall survival 30 days after a COVID-19 diagnosis. Overall survival probabilities were calculated using Kaplan-Meier estimator. Factors associated with mortality after COVID-19 diagnosis were examined using Cox proportional hazard models. Findings 318 HSCT recipients diagnosed with COVID-19 were reported to the CIBMTR. The median time from HSCT to COVID-19 diagnosis was 17 months (IQR 8-46) for allogeneic HSCT recipients and 23 months (8-51) for autologous HSCT recipients. The median follow-up of survivors was 21 days (IQR 8-41) for allogeneic HSCT recipients and 25 days (12-35) for autologous HSCT recipients. 34 (18%) of 184 allogeneic HSCT recipients were receiving immunosuppression within 6 months of COVID-19 diagnosis. Disease severity was mild in 155 (49%) of 318 patients, while severe disease requiring mechanical ventilation occurred in 45 (14%) of 318 patients-ie, 28 (15%) of 184 allogeneic HSCT recipients and 17 (13%) of 134 autologous HSCT recipients. At 30 days after the diagnosis of COVID-19, overall survival was 68% (95% CI 58-77) for recipients of allogeneic HSCT and 67% (55-78) for recipients of autologous HSCT. Age 50 years or older (hazard ratio 2•53, 95% CI 1•16-5•52; p=0•020); male sex (3•53; 1•44-8•67; p=0•006), and development of COVID-19 within 12 months of transplantation (2•67, 1•33-5•36; p=0•005) were associated with a higher risk of mortality among allogeneic HSCT recipients, and a disease indication of lymphoma was associated with a higher risk of mortality compared with plasma cell disorder or myeloma (2•41, [1•08-5•38]; p=0•033) in autologous HSCT recipients. Interpretation Recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival. These data emphasise the need for stringent surveillance and aggressive treatment measures in HSCT recipients who develop COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Sharma

Bhatt

Martin³

et al. 2021

The Lancet Haematology

320

408

View full text Add to dashboard Cite

show abstract

“…Lymphopenia and low ratio CD4/CD8 was associated with severe COVID-19 in this small cohort. (10) Our case series and the available experience reported from different countries showed that most of the children with cancer and post-HSCT have either asymptomatic or mild COVID-19 and these children have similar vulnerability and risk morbidity resulting from COVID-19 to healthy children. (11).…”

mentioning

confidence: 56%

COVID-19 in children with cancers and post-haematopiotic stem cell transplantation (HSCT) in Oman

Yazidi

Wali

Al‐Rawas

2020

Preprint

View full text Add to dashboard Cite

show abstract

“… 13 Additionally, a case series (8 patients) was recently reported from a Spanish pediatric transplant group. 14 The most common symptom was fever, 5/8 patients had radiographic abnormalities, 5/8 patients were hospitalized, and two of them needed intensive care. Six patients received HCQ, and the two patients admitted to ICU received in addition to HCQ, azithromycin, remdesivir, lopinavir/ritonavir, tocilizumab, siltuximab, and Anakinra.…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 post hematopoietic cell transplant, a report of 11 cases from a single center.

Adam

2020

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

In late 2019 the coronavirus disease‐2019 (COVID‐19) pandemic caused by SARS Coronavirus 2 (SARS‐CoV‐2) started in Wuhan, China. Cancer patients are immunosuppressed from their disease and the therapy they receive.Hematopoietic cell transplant (HCT) recipients are a subgroup of patients that are severely immunocompromised and may be at an even higher risk of a complicated course during this infection.We herein report the outcomes and course of 11 sequential cases of HCT recipients infected by SARS‐CoV‐2 treated in our center.The patients age ranged from 17 to 60 years, the duration from transplant to infection ranged from day +5 to 192 months, 6 patients were post allo-HCT, 4 post auto-HCT and one had both allo and auto-HCT. The presenting symptoms were not different from other viral illnesses. The majority had mild COVID-19 stage, while 3 had moderate stage on presentation. None of the patients required oxygen supplementation nor mechanical ventilation.

show abstract

COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)

Cited by 62 publications

References 7 publications

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

COVID-19 in children with cancers and post-haematopiotic stem cell transplantation (HSCT) in Oman

COVID‐19 post hematopoietic cell transplant, a report of 11 cases from a single center.

Contact Info

Product

Resources

About